Associations between weight gain, integrase inhibitors antiretroviral agents, and gut microbiome in people living with HIV: a cross-sectional study.

ABSTRACT: Dolutegravir and bictegravir are second-generation HIV integrase strand transfer inhibitors (INSTIs) that were previously associated with abnormal weight gain. This monocentric cross-sectional study investigates associations between weight gain during the first year after initiation of dolutegravir, bictegravir or other anchor drugs and gut microbiome diversity as well as taxa composition. The study enrolled 79 participants receiving dolutegravir, 32 receiving bictegravir and 10 receiving non-INSTI based regimens. Most of them were treatment experienced at initiation of those anchor drugs agents. Although weight gain was not linked to overall bacterial diversity, strong associations with specific taxa were demonstrated (FDR q < 0.01). Using multiple linear regression, we identified 4 disti

SUBMITTER: De Greef J 

PROVIDER: S-EPMC12218934 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature